Incyte’s Povorcitinib Shows Promise but Faces Competitive Challenges: Hold Rating Maintained

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Hold rating on Incyte, with a price target of $79.00.

Judah Frommer has given his Hold rating due to a combination of factors surrounding Incyte’s recent clinical trial data. The updated 24-week results from the STOP-HS program for povorcitinib showed promising efficacy, with a significant percentage of patients achieving HiSCR50, HiSCR75, and even complete clearance. However, the efficacy, while improved from earlier results, still falls short when compared to existing approved biologics.
Additionally, the safety profile remains consistent with previous reports, showing no new safety concerns, but the lack of a placebo beyond 12 weeks and the absence of a clear dose-dependent response limit the interpretation of the data. These factors suggest that while povorcitinib has potential, its competitive positioning in the market remains uncertain, justifying a Hold rating.

According to TipRanks, Frommer is an analyst with an average return of -3.2% and a 51.36% success rate. Frommer covers the Healthcare sector, focusing on stocks such as Galapagos, RegenXBio, and Incyte.